Vertex urged to address 'fatal inequality' in access to its cystic fibrosis drug

An advocacy group called Vertex Save Us is urging Vertex Pharmaceuticals to take steps to address the "fatal inequality" in access to its cystic fibrosis drug, Trikafta, STAT reported.

In a letter addressed to Vertex CEO Reshma Kewalramani, Vertex Save Us wrote that Vertex should provide its cystic fibrosis drugs at affordable prices, offer them on compassionate use basis and issue licenses to generic drugmakers in countries where the drugmaker doesn't intend to supply the drug in the near future.